OBJECTIVE

2

To evaluate the influence of pharmaceutical quality control on the efficiency and outcomes of standardized medication therapy management （MTM） services for patients with coronary heart disease by using Economic， Clinical and Humanistic Outcomes （ECHO） model.

METHODS

2

This study collected case data of coronary heart disease patients who received MTM services during January-March 2023 （pre-quality control implementation group，

n

＝96） and June-Au

gust 2023 （post-quality control implementation group，

n

＝164）. Using propensity score matching analysis， 80 patients were selected from each group. The study subsequently compared the economic， clinical， and humanistic outcome indicators of pharmaceutical services between the two matched groups.

RESULTS

2

There were no statistically significant differences in baseline data between the two groups after matching （

P

＞0.05）. Compared with pre-quality control implementation group， the daily treatment cost （16.26 yuan vs. 24.40 yuan，

P

＜0.001）， cost-effectiveness ratio [23.12 yuan/quality-adjusted life year （QALY） vs. 32.32 yuan/QALY，

P

＜0.001

]

， and the incidence of general adverse drug reactions （2.50% vs. 10.00%，

P

＝0.049） of post-quality control implementation group were decreased significantly； the utility value of the

EuroQol Five-Dimensional Questionnaire （0.74±0.06 vs. 0.71±0.07，

P

＝0.003）， the reduction in the number of medication related problems （1.0 vs. 0.5，

P

＜0.001）， the medication adherence score [（6.32±0.48） points vs. （6.10±0.37） points，

P

＝0.001

]

， and the satisfaction score [（92.56±1.52） points vs. （91.95±1.56） points，

P

＝0.013

]

all showed significant improvements. Neither group experienced serious adverse drug reactions. There was no statistically significant difference in the incidence of new adverse reactions between the two groups （1.25% vs. 3.75%，

P

＝0.310）.

CONCLUSIONS

2

Pharmaceutical quality control can improve the quality of pharmaceutical care， and the ECHO model can quantitatively evaluate the effect of MTM services， making pharmaceutical care better priced and more adaptable to social needs， thus being worthy of promotion.